{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:49:31Z","timestamp":1789764571970,"version":"4.0.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n HIV preexposure prophylaxis (PrEP) is highly effective in HIV prevention; telemedicine is a promising avenue for delivering PrEP care.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore telemedicine delivery of PrEP care (telePrEP) by the largest telePrEP company in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, single-arm cohort study used health record data of patients receiving telePrEP from MISTR LLC, a for-profit telehealth company, from November 27, 2018, to March 5, 2025. Patient characteristics and AIDSVu data were assessed to determine levels of PrEP use nationally. Retention in care was assessed for persons initiating PrEP in 2020, 2021, and 2022. Data were analyzed from March 5 to May 29, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Use of telePrEP.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the proportion of patients receiving telePrEP among all patients receiving PrEP in the US. Persons were classified as PrEP users if they received at least 1 day of prescribed PrEP in a calendar year.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n From 2018 through 2025, 162\u202f422 unique patients received telePrEP prescriptions from the telehealth company. Patients were predominantly young (mean [SD] age, 33.3 [10.3] years) and male (156 255 of 162 417 [96%]). Of 162 406 patients with data available, 19 610 (12%) were African American or Black, 12 075 (7%) were Asian, 39 744 (25%) were Hispanic or Latino, 82 222 (51%) were White, and 8755 (5%) were of other race or ethnicity. Most had not previously used PrEP (57 597 of 74 860 [77%]), and more than one-third (58 761 of 162 403 [36%]) were uninsured. Most users (131 875 [81%]) opted for home laboratory specimen collection as part of their care. TelePrEP use increased substantially from 6443 patients in 2020 to 110\u202f068 in 2024. TelePrEP as a proportion of all national PrEP use was 2% in 2020, 9% in 2022, and 19% in 2024. Retention in care was similar for cohorts starting in 2020, 2021, and 2022; 67% (16 716 of 24 976) to 73% (4571 of 6287) were retained in the calendar year after initiation, 42% (8408 of 19 916) to 43% (2732 of 6287) in the second year, and 32% (2043 of 6287) to 33% (6546 of 19 916) in the third year. Annual care reinitiation ranged from 2% to 5%.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that nearly 1 in 5 PrEP users in the US received their PrEP prescriptions from a single national telemedicine company in 2024. Most were new to PrEP and more than one-third were uninsured. TelePrEP provision benefits from facilitating policies such as Affordable Care Act coverage and the 340B Drug Pricing Program. The rapid growth and overall magnitude of telePrEP provision suggests that it is a critical part of HIV prevention infrastructure in the US that merits continued regulatory support.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.46792","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:00:26Z","timestamp":1764604826000},"page":"e2546792","source":"Crossref","is-referenced-by-count":5,"title":["Telemedicine Preexposure Prophylaxis Prescribing From a Large Online US Company"],"prefix":"10.1001","volume":"8","author":[{"given":"Aaron J.","family":"Siegler","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Hao Ernest","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Schukraft","sequence":"additional","affiliation":[{"name":"MISTR LLC, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mazzoni","sequence":"additional","affiliation":[{"name":"MISTR LLC, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Corbin-Gutierrez","sequence":"additional","affiliation":[{"name":"National Alliance of State & Territorial AIDS Directors, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Whitman-Walker Health, Washington, DC"},{"name":"Division of Infectious Diseases, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"9","key":"zoi251265r1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"zoi251265r3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.annepidem.2018.05.003","article-title":"Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race\/ethnicity, United States, 2015.","volume":"28","author":"Smith","year":"2018","journal-title":"Ann Epidemiol"},{"key":"zoi251265r4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annepidem.2025.04.017","article-title":"Estimating the population need for preexposure prophylaxis for HIV in the United States.","volume":"106","author":"Kourtis","year":"2025","journal-title":"Ann Epidemiol"},{"key":"zoi251265r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100738","article-title":"Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis.","volume":"33","author":"Sullivan","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"10","key":"zoi251265r6","doi-asserted-by":"publisher","DOI":"10.2196\/23173","article-title":"A data visualization and dissemination resource to support HIV prevention and care at the local level: analysis and uses of the AIDSVu public data resource.","volume":"22","author":"Sullivan","year":"2020","journal-title":"J Med Internet Res"},{"issue":"9","key":"zoi251265r8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.2105\/AJPH.2019.305172","article-title":"Geographic access to preexposure prophylaxis clinics among men who have sex with men in the United States.","volume":"109","author":"Siegler","year":"2019","journal-title":"Am J Public Health"},{"issue":"4","key":"zoi251265r9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz101","article-title":"Missed visits associated with future preexposure prophylaxis (PrEP) discontinuation among PrEP users in a municipal primary care health network.","volume":"6","author":"Spinelli","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"zoi251265r10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11904-020-00528-9","article-title":"A review of HIV pre-exposure prophylaxis streamlining strategies.","volume":"17","author":"Siegler","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"12","key":"zoi251265r11","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1080\/09540121.2021.2018567","article-title":"Evaluation of a telemedicine pilot program for the provision of HIV pre-exposure prophylaxis in the Southeastern United States.","volume":"34","author":"Player","year":"2022","journal-title":"AIDS Care"},{"issue":"9","key":"zoi251265r12","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1007\/s10461-024-04366-3","article-title":"Telehealth models for PrEP delivery: a systematic review of acceptability, implementation, and impact on the PrEP care continuum in the United States.","volume":"28","author":"Bonett","year":"2024","journal-title":"AIDS Behav"},{"issue":"1","key":"zoi251265r13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/QAI.0000000000001873","article-title":"Brief Report: PrEPTECH: a telehealth-based initiation program for HIV pre-exposure prophylaxis in young men of color who have sex with men: a pilot study of feasibility.","volume":"80","author":"Refugio","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"zoi251265r14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/OLQ.0000000000001017","article-title":"Iowa TelePrEP: a public-health-partnered telehealth model for human immunodeficiency virus preexposure prophylaxis delivery in a rural state.","volume":"46","author":"Hoth","year":"2019","journal-title":"Sex Transm Dis"},{"key":"zoi251265r15","doi-asserted-by":"publisher","DOI":"10.2196\/51023","article-title":"Online-mediated HIV pre-exposure prophylaxis care and reduced monitoring frequency for men who have sex with men: protocol for a randomized controlled noninferiority trial (EZI-PrEP Study).","volume":"12","author":"Groot Bruinderink","year":"2023","journal-title":"JMIR Res Protoc"},{"key":"zoi251265r16","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1054559","article-title":"Online HIV prophylaxis delivery: protocol for the ePrEP Kenya pilot study.","volume":"11","author":"Kiptinness","year":"2023","journal-title":"Front Public Health"},{"issue":"5","key":"zoi251265r17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000003375","article-title":"Effectiveness of PrEPTECH: findings from a 180-day randomized controlled trial of a pre-exposure prophylaxis telehealth intervention.","volume":"95","author":"Erenrich","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"zoi251265r18","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26173","article-title":"Telehealth effectiveness for pre-exposure prophylaxis delivery in Brazilian public services: the Combine! Study.","volume":"26","author":"Grangeiro","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"zoi251265r19","doi-asserted-by":"publisher","DOI":"10.2196\/55614","article-title":"Claims-based algorithm to identify pre-exposure prophylaxis indications for tenofovir disoproxil fumarate and emtricitabine prescriptions (2012-2014): validation study.","volume":"8","author":"Sullivan","year":"2024","journal-title":"JMIR Form Res"},{"issue":"12","key":"zoi251265r20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","article-title":"The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.","volume":"28","author":"Siegler","year":"2018","journal-title":"Ann Epidemiol"},{"issue":"5","key":"zoi251265r22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12529-023-10218-6","article-title":"Associations between health insurance coverage with HIV detection and prevention behaviors among individuals with undiagnosed HIV or at increased risk for HIV infection in the USA.","volume":"31","author":"Foley","year":"2024","journal-title":"Int J Behav Med"},{"key":"zoi251265r23","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1086\/522547","article-title":"Insurance coverage and access to HIV testing and treatment: considerations for individuals at risk for infection and for those with undiagnosed infection.","volume":"45","author":"Kates","year":"2007","journal-title":"Clin Infect Dis"},{"key":"zoi251265r25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.annepidem.2020.03.013","article-title":"Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.","volume":"45","author":"Siegler","year":"2020","journal-title":"Ann Epidemiol"},{"issue":"6","key":"zoi251265r26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-151-6-200909150-00002","article-title":"Ambulatory care among young adults in the United States.","volume":"151","author":"Fortuna","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi251265r28","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25252","article-title":"Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.","volume":"22","author":"Coy","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"zoi251265r29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/QAI.0000000000002833","article-title":"Long-term HIV pre-exposure prophylaxis trajectories among racial & ethnic minority patients: short, declining, & sustained adherence.","volume":"89","author":"Pyra","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"zoi251265r30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s11904-020-00533-y","article-title":"Understanding, contextualizing, and addressing PrEP stigma to enhance PrEP implementation.","volume":"17","author":"Calabrese","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"zoi251265r31","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1007\/s10461-018-2045-1","article-title":"Why I quit pre-exposure prophylaxis (PrEP)? a mixed-method study exploring reasons for prep discontinuation and potential re-initiation among gay and bisexual men.","volume":"22","author":"Whitfield","year":"2018","journal-title":"AIDS Behav"},{"issue":"3","key":"zoi251265r32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/QAI.0000000000002952","article-title":"Reasons for PrEP discontinuation after navigation at sexual health clinics: interactions among systemic barriers, behavioral relevance, and medication concerns.","volume":"90","author":"Unger","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"zoi251265r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309811","article-title":"Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084.","volume":"19","author":"Tolley","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"zoi251265r34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/QAI.0000000000003651","article-title":"Preferences for monthly oral PrEP over other PrEP modalities among a national sample of gay, bisexual, and other men who have sex with men in the United States.","volume":"99","author":"Gravett","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"zoi251265r35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/apc.2021.0033","article-title":"Why are patients switching from tenofovir disoproxil fumarate\/emtricitabine (Truvada) to tenofovir alafenamide\/emtricitabine (Descovy) for pre-exposure prophylaxis?","volume":"35","author":"D\u2019Angelo","year":"2021","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"zoi251265r37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/pop.2024.0012","article-title":"Long-term HIV pre-exposure prophylaxis persistence and reinitiation in Connecticut from 2012 to 2018.","volume":"27","author":"Tao","year":"2024","journal-title":"Popul Health Manag"},{"key":"zoi251265r2","unstructured":"Understanding PrEP in the U.S. PrEPVu. Accessed June 15, 2025. https:\/\/prepvu.org\/?"},{"key":"zoi251265r7","unstructured":"Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline. Centers for Disease Control and Prevention. December 2021. Accessed June 2, 2025. https:\/\/stacks.cdc.gov\/view\/cdc\/112360"},{"key":"zoi251265r21","unstructured":"Keisler-Starkey? K, Bunch? LN. Health insurance coverage in the United States: 2023. September 10, 2024. Accessed May 23, 2025. https:\/\/www.census.gov\/library\/publications\/2024\/demo\/p60-284.html"},{"key":"zoi251265r24","unstructured":"U.S. Census Bureau QuickFacts: United States. US Census Bureau. 2024. Accessed June 2, 2025. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045224"},{"key":"zoi251265r27","unstructured":"Blackfly Investments, LLC dba Molecular Testing Labs. October 11, 2024. Accessed August 27, 2025. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/blackfly-investments-llc-dba-molecularr-testing-labs-680324-10112024"},{"key":"zoi251265r36","unstructured":"Killelea? A, Johnson? J. PrEP coverage should follow clinical guidelines, not pharmaceutical agenda: a response to Hughes. Health Affairs Forefront. December 5, 2023. Accessed May 5, 2025. https:\/\/www.healthaffairs.org\/content\/forefront\/prep-coverage-should-follow-clinical-guidelines-not-pharmaceutical-agenda-response"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842105\/siegler_2025_oi_251265_1763735646.87582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:00:27Z","timestamp":1764604827000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.46792","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}